UPC APP 27016/2025

—·EP2279254 +1 more: NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY

Case details: Status
—
Action
Procedural application
Category
Case Management Orders
Parties: Claimants
Arbutus Biopharma Corporation
Genevant Sciences GmbH
Reps: Markus van Gardingen
Respondents
Moderna, Inc.
ModernaTX, Inc.
Moderna Belgium S.R.L.
Moderna Italy S.R.L.
Moderna France SASU
Moderna Biotech UK Limited
Moderna Switzerland GmbH
Moderna Poland SP. Z.O.O.
Moderna Portugal Unipessoal LDA
Moderna Sweden AB
Moderna Netherlands B.V.
Moderna Biotech Spain SL
Moderna Denmark ApS
Moderna Germany GmbH
Moderna Norway AS
Reps: Ruben Laddé; Joachim Renken
Division: The Hague LD
Judges: —
Technology: Biotechnology
Language: —
First decided: Jun 12, 2025

Decisions

2025-06-12
Application Rop 333
The Hague Local Division issued a procedural order on a R. 333 RoP application by various Moderna entities (defendants) regarding service and deadlines for filing the Statement of Defence in infringement proceedings brought by Arbutus Biopharma and Genevant Sciences. The court denied requests to stay service or extend deadlines for individual defendants not yet formally served, while setting a single consolidated deadline for all Moderna group defendants to file one joint Statement of Defence.
Legal issues:Service of process on multiple defendants (R. 333 RoP)Streamlining deadlines for corporate group defendantsConsolidated Statement of Defence by group defendantsExpeditious proceedings in pharmaceutical patent infringement

Documents